Abstract:
An immune composition containing Globo H or its fragment (e.g., SSEA3) and an adjuvant, e.g., a -GalCer, for eliciting immune responses against Globo H or its fragment and uses thereof in cancer treatment. Also disclosed is a method of treating cancer by inhibiting the activity of one of FUT1 and FUT2, both of which involve in Globo H biosynthesis.
Abstract:
Methods for assessing the risk level or survival/death probability of a neuroblastoma patient based on a number of microRNA signatures, optionally in combination with Dicer, Drosha, and age at diagnosis. Also disclosed herein is use of Dicer, Drosha, or both in suppressing neuroblastoma cell growth
Abstract:
Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided.
Abstract:
Glycosphingolipids (GSLs) bearing a-glucose (a-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with a-glucose (a-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with a-galactose (a-Gal) are disclosed. GSLs bearing a-glucose (a-Glc) and derivatives of a-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with a-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with a-Glc and derivatives thereof are provided.
Abstract:
An antibody against transmembrane coiled-coil domains protein 3 (TMCC3), or a binding fragment thereof, includes the CDR sequences set forth in the specification. A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane coiled-coil domains protein 3 (TMCC3). The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane coiled- coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.
Abstract:
Procedimiento diagnóstico de cáncer para los cánceres que son positivos para Globo H y positivos para Gb5, que comprende el suministro de una muestra que contiene anticuerpos de un sujeto del cual se sospecha que tiene cáncer, en donde dicha muestra es suero, saliva o líquido de ganglio linfático, la incubación de la muestra con Gb5 y uno o varios de Globo H, Bb2 y Bb3 para permitir que los anticuerpos de la muestra se fijen a Gb5 y a uno o varios de Globo H, Bb2 y Bb3, la medición de la cantidad de anticuerpos fijados a Gb5 y la cantidad de anticuerpos fijados a Globo H, a Bb2 o a Bb3, y la determinación de si el sujeto tiene el cáncer basándose en la cantidad de los anticuerpos fijados, en donde una proporción significativamente más alta de la cantidad de anticuerpos fijados a Globo H, Bb2 o Bb3 por la cantidad de anticuerpos fijados a Gb5, en comparación con la del sujeto sin cáncer, indica que el sujeto tiene un cáncer que es positivo para Globo H y positivo para Gb5.